Bond.az - H.C. Wainwright reiterated a Neutral rating and $50 price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) following Phase 3 hypochondroplasia trial results. The stock trades at $54.10 with a $10.46B market cap.
The analyst consensus of 1.65 indicates a Buy-leaning outlook, with targets ranging from $50 to $120. The trial showed a placebo-adjusted annual growth velocity of 2.33 cm/year at Week 52, with significant improvements in standing height, height Z-score, and arm span. No new safety signals emerged.
H.C. Wainwright noted BioMarin achieved the first pivotal win in hypochondroplasia, but competitive pressure from Ascendis, BridgeBio, and TYRA remains. These companies pursue similar CNP and FGFR3 approaches.
For comparison, VOXZOGO's achondroplasia label shows 1.57 cm/year growth velocity. The higher hypochondroplasia result may reflect a more responsive setting. Bond.az's analysis finds BMRN undervalued with a "GREAT" financial health score of 3.33.
